These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19666431)

  • 1. Nebivolol in patients with coronary slow flow: the right drug for the right case?
    Fragasso G
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):296-7. PubMed ID: 19666431
    [No Abstract]   [Full Text] [Related]  

  • 2. Unique effect of nebivolol on coronary hemodynamics: it's all a matter of flow.
    Lev EI; Battler A
    Cardiovasc Drugs Ther; 2007 Apr; 21(2):75-6. PubMed ID: 17417696
    [No Abstract]   [Full Text] [Related]  

  • 3. The effects of nebivolol on P wave duration and dispersion in patients with coronary slow flow.
    Güneş Y; Tuncer M; Güntekin U; Ceylan Y
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):290-5. PubMed ID: 19666430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional functions of the left ventricle in patients with coronary slow flow and the effects of nebivolol.
    Gunes Y; Tuncer M; Guntekin U; Ceylan Y; Sahin M; Simsek H
    Ther Adv Cardiovasc Dis; 2009 Dec; 3(6):441-6. PubMed ID: 19734185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow.
    Akçay A; Acar G; Kurutaş E; Sökmen A; Atli Y; Nacar AB; Tuncer C
    Turk Kardiyol Dern Ars; 2010 Jun; 38(4):244-9. PubMed ID: 20935430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
    Chlopicki S; Kozlovski VI; Gryglewski RJ
    J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension.
    Predel HG; Mainka W; Schillings W; Knigge H; Montiel J; Fallois J; Agrawal R; Schramm T; Graf C; Giannetti BM; Bjarnason-Wehrens B; Prinz U; Rost RE
    J Hum Hypertens; 2001 Oct; 15(10):715-21. PubMed ID: 11607802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ENOS is not activated by nebivolol in human failing myocardium.
    Brixius K; Song Q; Malick A; Boelck B; Addicks K; Bloch W; Mehlhorn U; Schwinger RH
    Life Sci; 2006 Aug; 79(13):1234-41. PubMed ID: 16716362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure].
    Wolf SC; Buck-Müller N; Görner S; Risler T; Brehm BR
    Med Klin (Munich); 2003 Jan; 98(1):1-6. PubMed ID: 12540987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial function in patients with coronary slow flow and the effects of nebivolol.
    Gunes Y; Gumrukcuoglu HA; Akdag S; Simsek H; Sahin M; Tuncer M
    Arq Bras Cardiol; 2011 Oct; 97(4):275-80. PubMed ID: 22011806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation.
    Kubli S; Feihl F; Waeber B
    Clin Pharmacol Ther; 2001 Apr; 69(4):238-44. PubMed ID: 11309552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.
    Cockcroft JR; Chowienczyk PJ; Brett SE; Chen CP; Dupont AG; Van Nueten L; Wooding SJ; Ritter JM
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1067-71. PubMed ID: 7562470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
    Toblli JE; Cao G; Casas G; Mazza ON
    Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol and endothelium dysfunction in salt-sensitive Dahl rats.
    van Zwieten PA
    J Hypertens; 2002 Mar; 20(3):357. PubMed ID: 11875295
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacological basis of anti-anginal therapy. II. Effects of nitrites and beta blocking agents (author's transl)].
    Penna M
    Rev Med Chil; 1978 Jul; 106(7):543-51. PubMed ID: 29329
    [No Abstract]   [Full Text] [Related]  

  • 19. beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?".
    Balligand JL
    J Am Coll Cardiol; 2009 Apr; 53(17):1539-42. PubMed ID: 19389565
    [No Abstract]   [Full Text] [Related]  

  • 20. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.